To test this hypothesis, we injected recombinant human (rh) FGF-2 or adenoviral vectors carrying a secreted form of rh-FGF-2 to young wild-type (WT) and HIV-transgenic26 (HIV-Tg26) mice without pre-existing renal disease, and assessed their renal outcome during their first weeks of life. The gene discussed is FGF2; the disease is kidney disorder.